Genomics & Transcriptomics
The analysis of DNA and RNA from samples (tumors, blood, organoids) allows identification of genetic alterations associated with response or resistance to treatments.
Provides a comprehensive view of the genes involved in the mechanisms of action and escape from ADCs.
In the OASIS program, Whole Exome Sequencing (WES) and bulk RNA sequencing (RNA-seq) are used together to provide a comprehensive molecular characterization of tumors. While WES identifies genetic alterations that may drive cancer development or influence treatment response, bulk RNA-seq reveals how these genetic changes affect gene activity within the tumor. Combining these two approaches helps capture tumor heterogeneity, understand mechanisms of response or resistance to antibody–drug conjugates (ADCs), and support the development of more precise and personalized therapeutic strategies.
How does it work?
Whole Exome Sequencing (WES)
Whole Exome Sequencing focuses on sequencing the protein-coding regions of the genome, which contain the majority of known disease-related genetic variants. By targeting these regions, WES enables the identification of key mutations, insertions, and deletions involved in cancer biology. This targeted yet comprehensive approach provides high-resolution information on tumor genetics while remaining efficient and scalable for clinical research applications.
Bulk RNA-sequencing
Bulk RNA sequencing is used to measure gene expression levels across entire tumor samples. This technology analyzes all RNA molecules simultaneously, offering a global view of which genes are active and how biological pathways are regulated. Bulk RNA-seq helps identify molecular signatures associated with treatment response, resistance, or disease progression, and complements genomic data by revealing the functional consequences of genetic alterations.